As of right now, Bionano Genomics Inc [BNGO] is trading at $1.46, up 8.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The BNGO shares have gain 14.06% over the last week, with a monthly amount drifted -9.32%, and not seem to be holding up well over a long-time horizon.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On 15, November 2023, LeddarTech Appoints Chris Stewart as Chief Financial Officer. In a post published today on Yahoo Finance, LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer (“CFO”).
From an analyst’s perspective:
Bionano Genomics Inc [NASDAQ: BNGO] stock has seen the most recent analyst activity on January 05, 2023, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $4.
Through the last year, Bionano Genomics Inc’s stock price ranged from $1.19 to $26.50. Currently, Wall Street analysts expect the stock to reach $12.33 within the next 12 months. Bionano Genomics Inc [NASDAQ: BNGO] shares were valued at $1.46 at the most recent close of the market. An investor can expect a potential return of 744.52% based on the average BNGO price forecast.
Analyzing the BNGO fundamentals
For Bionano Genomics Inc, (BNGO), the latest quarter sales were 9.32 billion, which represents an 29.04% increase. The company generates $68,647 in revenue per employee, while its income per employee is -$327,398. Gross Margin for this corporation currently stands at -9.55% with Operating Margin at -466.09%, Pretax Margin comes in at -470.15%, and Net Margin reading is -476.93%. To continue investigating profitability, this company’s Return on Assets is posted at -38.74, Equity is -45.21, Total Capital is -42.56, and Invested Capital is -43.86. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 4.47 and enduring liabilities to the whole assets at 3.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3833 points at the first support level, and at 1.3067 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5233, and for the 2nd resistance point, it is at 1.5867.
Bionano Genomics Inc [BNGO] reported earnings per share of -$1 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.97/share, meaning a difference of -$0.03 and a surprise factor of -3.10%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.24 per share as compared to estimates of -$1.03 per share, a difference of -$0.21 representing a surprise of -20.40%.
Ratios To Look Out For
It is important to note that Bionano Genomics Inc [NASDAQ:BNGO] has a current ratio of 2.60. On the other hand, the Quick Ratio is 3.55, and the Cash Ratio is 3.15. Considering the valuation of this stock, the price to sales ratio is 15.19, the price to book ratio is 1.74.
Transactions by insiders
Recent insider trading involved Mamuszka Hannah, Director, that happened on Jun 13 when 65789.0 shares were purchased. President and CEO, Holmlin R. Erik completed a deal on May 16 to buy 15000.0 shares. Meanwhile, Chief Financial Officer Stewart Christopher P. bought 50000.0 shares on May 12.